Nexalin Technology is a Houston neurostimulation issuer that spent the first half of the year trying to restart a United States commercial story through a home-use insomnia trial while the listing and the cash box failed together. The company is no longer a working cranial-stimulation franchise. It is a clinical-stage option on a De Novo path for the HALO Clarity headset, financed by thin public-market paper, and the mid-year print shows how little commercial activity remains underneath the pipeline narrative. Related-party device flow from the China partnership dropped to zero in the quarter, which leaves almost no revenue covering a multi-million operating cost base.
The strategic tension is that the trial started just as the exchange process accelerated. Mid-year cash sat just above $1 million after management sold short-term investments and tapped an at-the-market facility, against more than $3 million of operating cash use in six months. Stockholders' equity printed at $1.5 million, below the Nasdaq Capital Market floor of $2.5 million, and that letter landed on top of an earlier bid-price staff determination. A one-for-thirty reverse split in late August lifted the quote mechanically. It does not rebuild equity or fund Lindus Health through database lock.
What the second quarter actually shows is a company that initiated enrollment and bought the PONM digital layer it needed for a virtual clinic, then immediately had to finance survival. Alumni Capital's registered direct, a $15 million purchase facility, and a six-month Streeterville note arrived in the same August window as the Hearing Panel date. The open question is whether the panel and the new paper keep the ticker listed long enough for HALO enrollment to become a data event, or whether dilution and a listing loss consume the option first.